乳腺癌C-erbB-2、EGFR、PCNA和DNA含量与化疗及预后的关系

Breast cancer C-erbB-2, EGFR, PCNA and DNA content and chemotherapy and prognosis relations

目的:为探明表皮生长因子(EGFR)、增殖细胞核抗原(PCNA)、C-erbB-2癌基因和DNA含量在术前化疗组及未化疗组间表达的关系及意义。方法:应用免疫组织化学LSAB、BA法,对124例乳腺癌进行检测,同时行FCM、ICMDNA含量测定,全部病例均有ER、PR检测资料。结果:EGFR、C-erbB-2阳性率化疗组中表达的强度与其它组间比较差异显著(P<0.05)PCNA在CMF3化疗组中表达的强度与其它组间比较差显异显著(P<0.05),EGFR阳性者5年生存率显著低于EGFR阴性者(P<0.01),ER阳性者5年生存率显著高于ER阴性者(P<0.05)。结论:检测EGFR、PCNA、C-erbB-2和DNA含量有助于评估化疗疗效及预后。

Objective：In order to verify epidermis growth factor （EGFR）,multiplication cell nucleus antigen （PCNA）, the C-erbB-2 cancer gene and the DNA content the relations and the significance which the chemotherapy group and the chemotherapy group has not expressed in front of the technique.Method：application immunity histochemistry LSAB, the BA law, carries on the examination to 124 example breast cancers, with fashionable FCM, ICM the DNA content determination, the complete case of illness has ER, the PR examination material. Result：EGFR, in the C-erbB-2 masculine gender rate chemotherapy group expresses the intensity and other group of comparison difference are remarkable（P〈0.05）PCNA the intensity which expresses in the CMF3 chemotherapy group with during other groups quite is bad reveals differently remarkable（P〈0.05）,The EGFR masculine gender 5 years survival rate obviously is lower than the EGFR negative（P〈0.01）, The er masculine gender 5 years survival rate obviously is higher than the ER negative（P〈0.05）. Conclusion：Examines EGFR, PCNA, C-erbB-2 and the DNA content is helpful to the appraisal chemotherapy curative effect and the prognosis.